David Nutt – författare

Addictions have increased markedly in contemporary societies over the past decades. As well as widely acknowledged issues surrounding illegal substance addictions, there are increasing numbers of problems related to behavioural addictions such as the use of legal substances such as antidepressants and amphetamines. These addictions are concerning for a range of public policy fields, not least, public health and social cohesion. As a result, cohesive governance ofaddictive substances and behaviours is paramount to future public policy.This book is based on the findings of a five year, multidisciplinary project (Addictions and Lifestyles in Contemporary Europe - Reframing Addictions Project) studying the pace and impact of addictions in Europe, and is the concluding volume in the Governance of Addictive Substances and Behaviours series. Authored by 11 leading figures in the fields of public health, psychology, sociology, psychiatry, addiction studies, epidemiology, and social and public policy, the book takes a trulycomprehensive approach to the study of the current state of addiction governance in Europe and proposals for a future governance framework.No one country has yet got governance polices right. The project''s outcome is a plan for the redesign of addictions governance, which includes amendments to key metrics used in research, promoting individual-level to society-level scope of understanding in policy approaches, and bringing the impact of dependency on societal well-being to the fore.New Governance of Addictive Substances and Behaviours is an unprecedented study, both in terms of international reach and scope of issues addressed. It will be a key resource for anyone with an interest in research-driven European policy change in public health and the field of addictive substances and behaviours.

Addictions have increased markedly in contemporary societies over the past decades. As well as widely acknowledged issues surrounding illegal substance addictions, there are increasing numbers of problems related to behavioural addictions such as the use of legal substances such as antidepressants and amphetamines. These addictions are concerning for a range of public policy fields, not least, public health and social cohesion. As a result, cohesive governance ofaddictive substances and behaviours is paramount to future public policy.This book is based on the findings of a five year, multidisciplinary project (Addictions and Lifestyles in Contemporary Europe - Reframing Addictions Project) studying the pace and impact of addictions in Europe, and is the concluding volume in the Governance of Addictive Substances and Behaviours series. Authored by 11 leading figures in the fields of public health, psychology, sociology, psychiatry, addiction studies, epidemiology, and social and public policy, the book takes a trulycomprehensive approach to the study of the current state of addiction governance in Europe and proposals for a future governance framework.No one country has yet got governance polices right. The project''s outcome is a plan for the redesign of addictions governance, which includes amendments to key metrics used in research, promoting individual-level to society-level scope of understanding in policy approaches, and bringing the impact of dependency on societal well-being to the fore.New Governance of Addictive Substances and Behaviours is an unprecedented study, both in terms of international reach and scope of issues addressed. It will be a key resource for anyone with an interest in research-driven European policy change in public health and the field of addictive substances and behaviours.

Sleep dysfunction is one of the primary symptoms reported by patients with psychiatric disorders, and specifically those suffering from anxiety and depressive disorders. Conversely, primary insomnia and other sleep disorders produce symptoms of mood disturbance that are quite similar to those reported by patients with psychiatric disorders. Because of this overlap in the symptoms and treatments for insomnias and psychiatric disorders, it is important for cliniciansto be able to accurately identify the root cause of sleep dysfunction in individual patients in order to optimize treatment.Part of the Oxford Psychiatry Library series, Sleep Disorders provides clinicians with an overview of current understanding of sleep physiology, the pathophysiology of sleep disturbance, and the diagnosis and treatment of sleep disorders. This second edition includes new sections covering sleep problems in children, sleep in the elderly, and sleep in pregnancy and menopause, as well as new algorithms from the British Association of Psychopharmacology''s (BAP''s) new Consensus Guidelines on themanagement of sleep disorders.

Sleep dysfunction is one of the primary symptoms reported by patients with psychiatric disorders, and specifically those suffering from anxiety and depressive disorders. Conversely, primary insomnia and other sleep disorders produce symptoms of mood disturbance that are quite similar to those reported by patients with psychiatric disorders. Because of this overlap in the symptoms and treatments for insomnias and psychiatric disorders, it is important for cliniciansto be able to accurately identify the root cause of sleep dysfunction in individual patients in order to optimize treatment.Part of the Oxford Psychiatry Library series, Sleep Disorders provides clinicians with an overview of current understanding of sleep physiology, the pathophysiology of sleep disturbance, and the diagnosis and treatment of sleep disorders. This second edition includes new sections covering sleep problems in children, sleep in the elderly, and sleep in pregnancy and menopause, as well as new algorithms from the British Association of Psychopharmacology''s (BAP''s) new Consensus Guidelines on themanagement of sleep disorders.

There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs, however the last decade has seen a major renewal of interest in the therapeutic use of psychedelics and related drugs in psychiatry. Psilocybin (found in ''magic mushrooms'') has been used effectively for amelioration of distress in people with depression/anxiety in the context of potentially life-ending cancers, as well as for treatment-resistant depression and also addictions. MDMA (''ecstasy'') has shown efficacy for severe post-traumatic stress disorder, with enduring benefit. Other psychedelics, both plant-derived (e.g., ayahuasca) and synthetically produced (e.g., LSD) are also being investigated for their potential therapeutic value. These agents not only herald a new neurobiology but also allow an integration of psychotherapy with biological compounds that is truly novel and that challenges established psychiatric practice. Furthermore, the action of these agents on the brain allows an exploration of how the brain works to ''open up'' to psychotherapeutic healing. Published as part of the Oxford Psychiatry Library series, the book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.

There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs, however the last decade has seen a major renewal of interest in the therapeutic use of psychedelics and related drugs in psychiatry. Psilocybin (found in ''magic mushrooms'') has been used effectively for amelioration of distress in people with depression/anxiety in the context of potentially life-ending cancers, as well as for treatment-resistant depression and also addictions. MDMA (''ecstasy'') has shown efficacy for severe post-traumatic stress disorder, with enduring benefit. Other psychedelics, both plant-derived (e.g., ayahuasca) and synthetically produced (e.g., LSD) are also being investigated for their potential therapeutic value. These agents not only herald a new neurobiology but also allow an integration of psychotherapy with biological compounds that is truly novel and that challenges established psychiatric practice. Furthermore, the action of these agents on the brain allows an exploration of how the brain works to ''open up'' to psychotherapeutic healing. Published as part of the Oxford Psychiatry Library series, the book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.

There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs, however the last decade has seen a major renewal of interest in the therapeutic use of psychedelics and related drugs in psychiatry. Psilocybin (found in 'magic mushrooms') has been used effectively for amelioration of distress in people with depression/anxiety in the context of potentially life-ending cancers, as well as for treatment-resistant depression and also addictions. MDMA ('ecstasy') has shown efficacy for severe post-traumatic stress disorder, with enduring benefit. Other psychedelics, both plant-derived (e.g., ayahuasca) and synthetically produced (e.g., LSD) are also being investigated for their potential therapeutic value. These agents not only herald a new neurobiology but also allow an integration of psychotherapy with biological compounds that is truly novel and that challenges established psychiatric practice. Furthermore, the action of these agents on the brain allows an exploration of how the brain works to 'open up' to psychotherapeutic healing. Published as part of the Oxford Psychiatry Library series, the book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.

Addictions have increased markedly in contemporary societies over the past decades. As well as widely acknowledged issues surrounding illegal substance addictions, there are increasing numbers of problems related to behavioural addictions such as the use of legal substances such as antidepressants and amphetamines. These addictions are concerning for a range of public policy fields, not least, public health and social cohesion. As a result, cohesive governance of addictive substances and behaviours is paramount to future public policy.This book is based on the findings of a five year, multidisciplinary project (Addictions and Lifestyles in Contemporary Europe - Reframing Addictions Project) studying the pace and impact of addictions in Europe, and is the concluding volume in the Governance of Addictive Substances and Behaviours series. Authored by 11 leading figures in the fields of public health, psychology, sociology, psychiatry, addiction studies, epidemiology, and social and public policy, the book takes a truly comprehensive approach to the study of the current state of addiction governance in Europe and proposals for a future governance framework.No one country has yet got governance polices right. The project's outcome is a plan for the redesign of addictions governance, which includes amendments to key metrics used in research, promoting individual-level to society-level scope of understanding in policy approaches, and bringing the impact of dependency on societal well-being to the fore.New Governance of Addictive Substances and Behaviours is an unprecedented study, both in terms of international reach and scope of issues addressed. It will be a key resource for anyone with an interest in research-driven European policy change in public health and the field of addictive substances and behaviours.

Depression is a major cause of morbidity throughout the world. Given that between 8 and 12% of the population (in most countries) will suffer from depression at some point in their lives, it is clearly a significant public health problem. As our knowledge of this illness has expanded in recent years, it has become clear that depression can no longer be viewed as a simple disorder of the brain. It has to be seen as a series of behavioural and biological changes that span mind, brain, genes, and body - indeed affecting both psychological and physical health. This book brings together world leaders in research on depression, to discuss, for the first time, in an interdisciplinary setting, both classical and innovative ideas to understand this devastating disorder. It presents neurobiological, psychological, genetic and evolutionary models, with a particular emphasis on the mechanisms linking the brain to the endocrine and the immune systems, and therefore linking depression to physical health. Opening with a powerful, personal, account of depression, that conveys something of the all-consuming, debilitating, nature of this illness, the book then presents cutting edge research from those at the frontiers of work in this area. The book will be valuable for all psychiatrists, clinical psychologists and neuroscientists seeking a state-of-the-art of this global problem

In the past two decades, there have been astonishing advances in our understanding of the neurobiological basis and nature of drug addiction. We now know the initial molecular sites of action, at identified receptors, of virtually all of the major drugs of abuse including cocaine, heroin, and amphetamine, as well as legal drugs such as nicotine and alcohol. We also understand the main components of a 'reward system' and its connections to major brain regions involved in motivation and emotion, such as the amygdala, hippocampus, and prefrontal cortex. The Neurobiology of Addiction describes the latest advances in our understanding of addiction. It brings together world class researchers to debate the nature and extent of addiction, as well as its causes, consequences, and treatment. The focus of the book is on the brain processes underlying addiction, in terms of neural systems, neurochemical basis, and molecular changes. Several types of addiction are discussed ranging from illicit drugs - cocaine, amphetamine, and heroin to legal drugs - alcohol and nicotine. In addition, it explores increasingly common behavioural addictions such as gambling and obesity. Included are chapters on vulnerability to addiction, genetic factors, opponent motivational processes, animal models, relapse, cognitive deficits associated with drug abuse, new pharmacological treatments, and current controversies concerning different neuropsychological theories of addiction. Throughout, it reports on cutting edge research using brain imaging, and state of the art molecular methodology.The book will make fascinating reading for students and teachers in the field of neuroscience, pharmacology and psychology, as well as experts in the field.

Sleep dysfunction is one of the primary symptoms reported by patients with psychiatric disorders, and specifically those suffering from anxiety and depressive disorders. Conversely, primary insomnia and other sleep disorders produce symptoms of mood disturbance that are quite similar to those reported by patients with psychiatric disorders. Because of this overlap in the symptoms and treatments for insomnias and psychiatric disorders, it is important for clinicians to be able to accurately identify the root cause of sleep dysfunction in individual patients in order to optimize treatment. Part of the Oxford Psychiatry Library series, Sleep Disorders provides clinicians with an overview of current understanding of sleep physiology, the pathophysiology of sleep disturbance, and the diagnosis and treatment of sleep disorders. This second edition includes new sections covering sleep problems in children, sleep in the elderly, and sleep in pregnancy and menopause, as well as new algorithms from the British Association of Psychopharmacology's (BAP's) new Consensus Guidelines on the management of sleep disorders.

Post Traumatic Stress Disorder can be one of the most disabling of all the anxiety disorders and is frequently misdiagnosed and ineffectively treated. It is also an area in which there have been recent major advances. This book sets out to solve this problem, presenting doctors with practical guidance and at the same time a state-of-the-art summary of all the latest developments.

The dangers of illegal drugs are well known and rarely disputed, but how harmful are alcohol and tobacco by comparison? The issue of what a drug is and how we should live with them affects us all: parents, teachers, users – anyone who has taken a painkiller or drunk a glass of wine. Written by renowned psychiatrist, Professor David Nutt, Drugs without the hot air casts a refreshingly honest light on drugs and answers crucial questions that are rarely ever disputed. What are we missing by banning medical research into magic mushrooms, LSD and cannabis? Can they be sources of valuable treatments? How can psychedelics treat depression?Drugs without the hot air covers a wide range of topics, from addiction and whether addictive personalities exist to the role of cannabis in treating epilepsy, an overview on the opioid crisis, and an assessment of how harmful vaping is. This new expanded and revised second edition includes even more details on international policies, particularly in the US. David's research has won international support, reducing drug-related harm by introducing policies that are founded on scientific evidence. But there is still a lot to be done. Accessibly written, this much-awaited second edition is an important book for everyone that brings us all up to date with the 'war of drugs'.

This book covers the entire field of research in the area of minor tranquillizers and its application to current clinical practice in the treatment of anxiety and insomnia. These drugs are principally the benzodiazepines and related drugs with a similar mechanism of action, such as zolpidem and zopiclone. The molecular mechanism of action of benzodiazepines is described, focussing on the interaction of these drugs with the different isoform of the GABAA^O >receptor, and the consequences of this for brain function. Recent advances in this knowledge have provided a framework for defining the physiochemical nature of the interaction between such drugs and their receptor protein, and thus pave the way for the design of new anxiolytic and hypnotic drugs. The animal models available for evaluating the potential of such new therapeutic agents in the treatment of anxiety and insomnia are discussed. Furthermore, understanding of the physiological regulation of the GABAA receptor may provide insights into the aetiopathology of these diseases. The clinical use of benzodiazepines and related drugs in the treatment of anxiety, insomnia, epilepsy and as anaesthetics are explored. The advantages and limitations of such treatments are discussed, and the impact of drugs evaluated. A chapter is devoted to the issue of independence, the clinical pertinence of tolerence and dependence, and evaluates treatment options that may minimise the risk of dependence.

This book covers the entire field of research in the area of minor tranquillizers and its application to current clinical practice in the treatment of anxiety and insomnia. These drugs are principally the benzodiazepines and related drugs with a similar mechanism of action, such as zolpidem and zopiclone. The molecular mechanism of action of benzodiazepines is described, focussing on the interaction of these drugs with the different isoform of the GABAA^O >receptor, and the consequences of this for brain function. Recent advances in this knowledge have provided a framework for defining the physiochemical nature of the interaction between such drugs and their receptor protein, and thus pave the way for the design of new anxiolytic and hypnotic drugs. The animal models available for evaluating the potential of such new therapeutic agents in the treatment of anxiety and insomnia are discussed. Furthermore, understanding of the physiological regulation of the GABAA receptor may provide insights into the aetiopathology of these diseases. The clinical use of benzodiazepines and related drugs in the treatment of anxiety, insomnia, epilepsy and as anaesthetics are explored. The advantages and limitations of such treatments are discussed, and the impact of drugs evaluated. A chapter is devoted to the issue of independence, the clinical pertinence of tolerence and dependence, and evaluates treatment options that may minimise the risk of dependence.

Post Traumatic Stress Disorder can be one of the most disabling of all the anxiety disorders and is frequently misdiagnosed and ineffectively treated It is also an area in which there have been recent major advances This book sets out to solve this problem, presenting doctors with practical guidance and at the same time a state-of-the-art summary o